Biohaven Pharmaceutical Holding ROA 2016-2022 | BHVN
Current and historical return on assets (ROA) values for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Biohaven Pharmaceutical Holding ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2022-06-30 |
$-1.02B |
$1.39B |
-82.24% |
| 2022-03-31 |
$-0.79B |
$1.37B |
-71.49% |
| 2021-12-31 |
$-0.85B |
$1.08B |
-83.51% |
| 2021-09-30 |
$-0.87B |
$1.13B |
-94.46% |
| 2021-06-30 |
$-0.89B |
$0.85B |
-107.17% |
| 2021-03-31 |
$-0.86B |
$1.00B |
-118.65% |
| 2020-12-31 |
$-0.77B |
$0.69B |
-126.46% |
| 2020-09-30 |
$-0.70B |
$0.78B |
-160.55% |
| 2020-06-30 |
$-0.61B |
$0.42B |
-174.50% |
| 2020-03-31 |
$-0.64B |
$0.53B |
-174.71% |
| 2019-12-31 |
$-0.53B |
$0.00B |
-179.74% |
| 2019-09-30 |
$-0.43B |
$0.44B |
-118.50% |
| 2019-06-30 |
$-0.39B |
$0.49B |
-127.44% |
| 2019-03-31 |
$-0.22B |
$0.25B |
-89.58% |
| 2018-12-31 |
$-0.24B |
$0.29B |
-112.94% |
| 2018-09-30 |
$-0.21B |
$0.20B |
-119.94% |
| 2018-06-30 |
$-0.19B |
$0.24B |
-111.33% |
| 2018-03-31 |
$-0.20B |
$0.13B |
-119.64% |
| 2017-12-31 |
$-0.14B |
$0.15B |
-91.75% |
| 2017-09-30 |
$-0.14B |
$0.19B |
-113.58% |
| 2017-06-30 |
$-0.12B |
$0.21B |
-163.46% |
| 2017-03-31 |
$-0.08B |
$0.06B |
-386.21% |
| 2016-12-31 |
$-0.06B |
$0.03B |
-948.15% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.535B |
$0.463B |
|
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
|
